NeuroMetrix Company Profile (NASDAQ:NURO)

About NeuroMetrix (NASDAQ:NURO)

NeuroMetrix logoNeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NURO
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.66 million
  • Outstanding Shares: 2,126,000
Average Prices:
  • 50 Day Moving Avg: $1.96
  • 200 Day Moving Avg: $1.87
  • 52 Week Range: $0.38 - $4.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.22
  • P/E Growth: -0.01
Sales & Book Value:
  • Annual Revenue: $15.72 million
  • Price / Sales: 0.27
  • Book Value: $2.83 per share
  • Price / Book: 0.70
  • EBIDTA: ($13,270,000.00)
  • Net Margins: -83.92%
  • Return on Equity: -209.56%
  • Return on Assets: -135.03%
  • Current Ratio: 2.13%
  • Quick Ratio: 1.73%
  • Average Volume: 47,958 shs.
  • Beta: 0.38
  • Short Ratio: 1.7

Frequently Asked Questions for NeuroMetrix (NASDAQ:NURO)

What is NeuroMetrix's stock symbol?

NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."

When did NeuroMetrix's stock split? How did NeuroMetrix's stock split work?

NeuroMetrix's stock reverse split on the morning of Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of NeuroMetrix stock prior to the reverse split would have 13 shares after the split.

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) posted its quarterly earnings data on Thursday, July, 20th. The company reported ($2.49) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.83) by $0.34. The business earned $4.31 million during the quarter, compared to analysts' expectations of $4.40 million. NeuroMetrix had a negative return on equity of 209.56% and a negative net margin of 83.92%. View NeuroMetrix's Earnings History.

When will NeuroMetrix make its next earnings announcement?

NeuroMetrix is scheduled to release their next quarterly earnings announcement on Wednesday, October, 18th 2017. View Earnings Estimates for NeuroMetrix.

Where is NeuroMetrix's stock going? Where will NeuroMetrix's stock price be in 2017?

2 brokers have issued 12-month price targets for NeuroMetrix's shares. Their predictions range from $16.00 to $36.00. On average, they anticipate NeuroMetrix's share price to reach $26.00 in the next year. View Analyst Ratings for NeuroMetrix.

Who are some of NeuroMetrix's key competitors?

Who are NeuroMetrix's key executives?

NeuroMetrix's management team includes the folowing people:

  • Shai N. Gozani M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer, Secretary
  • Thomas T. Higgins, Chief Financial Officer, Senior Vice President, Treasurer
  • Francis X. McGillin, Senior Vice President, General Manager - Consumer Wearables
  • David E. Goodman M.D., Independent Director
  • Allen J. Hinkle M.D., Independent Director
  • Nancy E. Katz, Independent Director
  • Timothy R. Surgenor, Independent Director
  • David Van Avermaete, Independent Director

How do I buy NeuroMetrix stock?

Shares of NeuroMetrix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeuroMetrix's stock price today?

One share of NeuroMetrix stock can currently be purchased for approximately $1.97.

MarketBeat Community Rating for NeuroMetrix (NASDAQ NURO)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  123
MarketBeat's community ratings are surveys of what our community members think about NeuroMetrix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NeuroMetrix (NASDAQ:NURO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.00 (1,219.80% upside)

Analysts' Ratings History for NeuroMetrix (NASDAQ:NURO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/15/2017HC WainwrightSet Price TargetBuy$16.00LowView Rating Details
10/21/2016Rodman & RenshawReiterated RatingBuy$36.00N/AView Rating Details
2/29/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
(Data available from 9/19/2015 forward)


Earnings History for NeuroMetrix (NASDAQ:NURO)
Earnings by Quarter for NeuroMetrix (NASDAQ:NURO)
Earnings History by Quarter for NeuroMetrix (NASDAQ NURO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/18/2017N/AView Earnings Details
7/20/2017Q2 2017($2.83)($2.49)$4.40 million$4.31 millionViewN/AView Earnings Details
4/20/2017Q1 2017($3.92)($7.28)$4.17 million$4.31 millionViewN/AView Earnings Details
1/26/2017Q416($6.00)($4.16)$3.48 million$3.70 millionViewListenView Earnings Details
10/20/2016Q316($6.56)($6.08)$3.01 million$3.39 millionViewListenView Earnings Details
7/21/2016Q216($7.44)($42.96)$1.22 million$2.65 millionViewListenView Earnings Details
4/21/2016Q116($7.60)($8.00)$2.65 million$2.28 millionViewListenView Earnings Details
10/22/2015Q315($0.64)($2.08)$6.47 million$2.10 millionViewListenView Earnings Details
7/22/2015Q215($3.84)$9.80 million$1.22 millionViewListenView Earnings Details
2/12/2015Q414($2.88)$4.62 million$1.41 millionViewN/AView Earnings Details
7/24/2014Q413($6.80)$1.16 million$1.34 millionViewN/AView Earnings Details
2/13/2014($6.96)ViewListenView Earnings Details
10/23/2013Q313($2.08)$1.77 million$1.31 millionViewListenView Earnings Details
7/25/2013Q2 2013($7.36)$2.20 million$1.20 millionViewN/AView Earnings Details
2/3/2011($1.36)($1.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NeuroMetrix (NASDAQ:NURO)
Current Year EPS Consensus Estimate: $-11.20 EPS
Next Year EPS Consensus Estimate: $-1.62 EPS


Dividend History for NeuroMetrix (NASDAQ:NURO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NeuroMetrix (NASDAQ:NURO)
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 6.53%
Insider Trades by Quarter for NeuroMetrix (NASDAQ:NURO)
Institutional Ownership by Quarter for NeuroMetrix (NASDAQ:NURO)
Insider Trades by Quarter for NeuroMetrix (NASDAQ:NURO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/21/2017Thomas T HigginsInsiderBuy1,000$2.83$2,830.00View SEC Filing  
6/16/2017Shai GozaniCEOBuy3,500$2.90$10,150.00View SEC Filing  
6/15/2017Thomas T HigginsInsiderBuy3,500$2.98$10,430.00View SEC Filing  
6/14/2017Shai GozaniCEOBuy5,000$2.97$14,850.00View SEC Filing  
6/14/2017Thomas T HigginsInsiderBuy2,300$2.97$6,831.00View SEC Filing  
11/1/2016Shai GozaniCEOBuy3,000$1.31$3,930.00View SEC Filing  
10/28/2016Thomas T HigginsInsiderBuy3,000$1.32$3,960.00View SEC Filing  
10/27/2016Shai GozaniCEOBuy6,000$1.32$7,920.00View SEC Filing  
8/31/2016Thomas T HigginsCFOBuy1,400$1.41$1,974.00View SEC Filing  
8/18/2016Shai GozaniCEOBuy5,000$1.49$7,450.00View SEC Filing  
8/12/2016Thomas T HigginsInsiderBuy2,000$1.45$2,900.00View SEC Filing  
6/1/2016Shai GozaniCEOBuy2,500$1.71$4,275.00View SEC Filing  
5/23/2016Francis X McgillinVPBuy1,000$1.65$1,650.00View SEC Filing  
5/19/2016Shai GozaniCEOBuy12,000$1.55$18,600.00View SEC Filing  
5/19/2016Thomas T HigginsCFOBuy3,200$1.54$4,928.00View SEC Filing  
8/28/2015Thomas T HigginsCFOBuy4,500$0.92$4,140.00View SEC Filing  
8/20/2015Thomas T HigginsCFOBuy5,500$0.91$5,005.00View SEC Filing  
8/11/2015Shai GozaniCEOBuy16,300$0.91$14,833.00View SEC Filing  
11/9/2012Shai GozaniCEOBuy26,800$0.55$14,740.00View SEC Filing  
8/27/2012Krishnamurthy BalachandranCOOBuy5,000$0.67$3,350.00View SEC Filing  
8/21/2012Thomas T HigginsCFOBuy5,000$0.64$3,200.00View SEC Filing  
8/13/2012Krishnamurthy BalachandranCOOBuy5,000$0.70$3,500.00View SEC Filing  
8/8/2012Thomas T HigginsCFOBuy5,000$0.70$3,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NeuroMetrix (NASDAQ:NURO)
Latest Headlines for NeuroMetrix (NASDAQ:NURO)
DateHeadline logoHead to Head Contrast: Tandem Diabetes Care (TNDM) versus NeuroMetrix (NURO) - September 19 at 12:56 PM logoBefore You Buy NeuroMetrix Inc’s (NURO), You Should Consider This - September 19 at 5:44 AM logoNeuroMetrix (NURO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 12 at 7:16 AM logoComparing Asante Solutions (PUMP) & NeuroMetrix (NURO) - September 9 at 6:44 PM logoSyneron Medical (ELOS) vs. NeuroMetrix (NURO) Financial Analysis - September 8 at 10:28 PM logoNeuroMetrix Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12th, 2017 - September 6 at 7:02 AM logoTwo Studies Derived from Quell Health Cloud to be Presented at Upcoming PAINWeek National Conference - September 1 at 6:31 AM logoNeuroMetrix Teams Up with U.S. Pain Foundation to Raise Awareness of Chronic Pain - August 30 at 7:25 AM logoComparing Asante Solutions (PUMP) and NeuroMetrix (NURO) - August 17 at 4:50 AM logoNeuroMetrix Announces Issuance of New U.S. Patent for Automated Control of Quell Therapy During Sleep - August 15 at 4:32 PM logoNeuroMetrix Announces DPNCheck Distribution Agreement with Fukuda Denshi in Japan - August 4 at 6:27 AM logoNeuroMetrix Announces Shipment of 100000 - Business Wire (press release) - July 29 at 5:41 AM logoNeuroMetrix Announces Shipment of 100,000th Quell Device Since Launch in 2015 - July 28 at 6:18 AM logoNeuroMetrix, Inc. :NURO-US: Earnings Analysis: Q2, 2017 By the Numbers : July 24, 2017 - July 25 at 6:19 AM logoNeuroMetrix Reports Q2 2017 Financial Results - Business Wire (press release) - July 22 at 7:05 AM logoNeuroMetrix, Inc. (NURO) Announces Earnings Results - July 21 at 11:05 AM logoInvestor Network: NeuroMetrix, Inc. to Host Earnings Call - July 21 at 4:30 AM logoNeuroMetrix Reports Q2 2017 Financial Results - July 21 at 4:30 AM logoEdited Transcript of NURO earnings conference call or presentation 20-Jul-17 12:00pm GMT - July 21 at 4:30 AM logoNeuroMetrix, Inc. Announces Date for 2017 Second Quarter Financial Results Conference Call - Business Wire (press release) - July 13 at 7:27 AM logoNeuroMetrix, Inc. Announces Date for 2017 Second Quarter Financial Results Conference Call - July 13 at 7:27 AM logoNeuroMetrix, Inc. (NURO) - July 12 at 6:30 AM logoNeuroMetrix Announces $7.0 Million Private Placement of Preferred Stock - July 11 at 6:04 AM logoNeuroMetrix Reports Promotion of Michael MacDonald to Senior Vice President and General Manager of Diagnostics - July 6 at 7:35 AM logoZacks Investment Research Upgrades NeuroMetrix, Inc. (NASDAQ:NURO) to Buy - July 5 at 7:32 AM logoNeuroMetrix Provides Update on Quell Health Cloud Including ... - Business Wire (press release) - June 27 at 6:49 AM logoNeuroMetrix Provides Update on Quell Health Cloud Including Promotion of Dr. Xuan Kong to Chief Data Scientist - June 27 at 6:49 AM logoNeuroMetrix Provides Update on Quell Wearable Pain Relief Clinical Program - June 23 at 7:30 PM logoInsider Buying: NeuroMetrix, Inc. (NURO) CEO Acquires 3,500 Shares of Stock - June 16 at 4:50 PM logoHC Wainwright Analysts Give NeuroMetrix, Inc. (NURO) a $16.00 Price Target - June 16 at 1:16 AM logoInsider Buying: NeuroMetrix, Inc. (NURO) Insider Acquires 3,500 Shares of Stock - June 15 at 8:08 PM logoNeuroMetrix, Inc. (NURO) CEO Acquires $14,850.00 in Stock - June 14 at 4:28 PM logoToday's Research Reports on Stocks to Watch: Cleantech Solutions and NeuroMetrix - June 14 at 9:14 AM logoNeuroMetrix (NURO) Presents At 7th Annual LD Micro Invitational Conference - Slideshow - June 9 at 7:07 PM logoNeuroMetrix to Present at the Marcum Microcap Conference on June 16, 2017 - June 8 at 9:45 AM logoNeuroMetrix Exhibits Quell Wearable Technology at 31st Annual SLEEP Meeting - June 6 at 7:39 PM logoNeurometrix Inc (NURO) Downgraded to Strong Sell at ValuEngine - June 3 at 11:58 PM logoNeuroMetrix to Present at the LD Micro Invitational Conference on June 6, 2017 - May 30 at 9:04 AM logoNeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Pain Relief Technology - May 22 at 6:10 PM logoNeurometrix Inc (NURO) Upgraded to Hold at Zacks Investment Research - May 18 at 2:50 PM logoNeuroMetrix Wins SBANE New England Innovation Award - May 17 at 6:52 PM logoNeuroMetrix (NURO) Says Preliminary Results from Study Evaluating Quell in Chemotherapy-Induced Peripheral Neuropathy to be Presented at APS Meeting - May 16 at 10:10 AM logoNeuroMetrix Launches the LivingQuell Blog, a New Platform for Exploring Perspectives on Chronic Pain - May 16 at 10:10 AM logoPreliminary Results from Clinical Study Evaluating Use of Quell in Chemotherapy-Induced Peripheral Neuropathy to be presented at the American Pain Society Annual Meeting - May 15 at 6:14 PM logoNeuroMetrix (NURO) Declares 1-for-8 Reverse Stock Split - May 13 at 8:20 AM logoNeuroMetrix Announces One-for-Eight Reverse Split - May 11 at 7:24 PM logoNeuroMetrix (NURO) Announces Expansion of International Intellectual Property Assets for Quell - May 8 at 6:24 PM logoNeuroMetrix Reports Substantial Expansion of International Intellectual Property Assets for Quell Wearable Pain Relief Technology - May 8 at 12:15 PM logoNeuroMetrix Hosts Inaugural Quell User Event - May 5 at 7:11 PM logoNeurometrix (NURO) Getting Somewhat Positive Media Coverage, Analysis Finds - May 3 at 3:24 PM



NeuroMetrix (NURO) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff